Results 171 to 180 of about 817,135 (264)

Physiotherapist and nurse perspectives on the acceptability and timing of patient-reported outcome measures in clinical practice: Balancing standardisation and flexibility. [PDF]

Qual Life Res
Nikolovski J, Franklin M, Morton RL, Armstrong M, Hartas G, Rossiter B, Fagan M, Tinsley M, Levesque JF, Sutherland K, Mercieca-Bebber R, Snyder C, Aiyegbusi OL, Power R, De Lisser-Howarth T, Troiani JP, Maher J, Leonard J, Elias K, Rutherford C.   +19 more
europepmc   +1 more source

USP29‐regulated noncanonical stabilization of the hypoxia‐inducible factor‐α in aggressive prostate cancer

Molecular Oncology, EarlyView.
We identify USP29 as the only DUB mirroring CA9 expression, a marker of hypoxia and HIF pathway activation associated with PCA aggressiveness. USP29 stabilizes HIF‐1α and HIF‐2α via a noncanonical mechanism that is independent of PHD/pVHL activity yet relies on proteasomal regulation, establishing USP29 as a previously unrecognized regulator of hypoxic
Amelie S Schober, Leire Moreno‐Cugnon, Laura Martínez‐Pérez, Amaia Ercilla, Amaia Zabala‐Letona, Adrián Vicente‐Barrueco, Maider Fagoaga‐Eugui, Saioa Garcia‐Longarte, Blanca Calle‐Ciborro, Encarnación Pérez‐Andrés, Onintza Carlevaris, Sara Pozo, Isabel Mendizabal, Ugo Mayor, Arkaitz Carracedo, Violaine Sée, Edurne Berra   +16 more
wiley   +1 more source

Patient experience and procedural safety in prostate biopsy: interpreting patient-reported outcome measures in the era of transperineal biopsy. [PDF]

Transl Androl Urol
Sordelli F, Uleri A, Ploussard G, Baboudjian M.   +3 more
europepmc   +1 more source

Patient‐reported outcomes (PROs) versus patient‐reported outcome measures (PROMs)—Is there a difference? [PDF]

Clinical and Experimental Dental Research, 2018
openaire   +2 more sources

Finding novel vulnerabilities of hypomorphic BRCA1 alleles

Molecular Oncology, EarlyView.
Synthetic lethality screens performed to identify novel vulnerabilities often model complete gene loss, thereby overlooking patient‐derived hypomorphic mutations. In this study, we have performed genome‐wide CRISPR screens on BRCA1 hypomorphic mutations, showing BRCA1I26A behaves like wild‐type, while BRCA1R1699Q mimics deficiency. Furthermore, we have
Anne Schreuder, Klaas de Lint, Hồ Mỹ Phúc Võ, Mariana M. Góis, Rosalie A. Kampen, Marta San Martin Alonso, Ilse Nootenboom, Veronica Garzero, Tiemen J. Wendel, Rob M. F. Wolthuis, Sylvie M. Noordermeer   +10 more
wiley   +1 more source

Unlocking patient insights: a prospective study on patient reported outcome measures in thoracic surgery. [PDF]

J Cardiothorac Surg
Andreas MN, Jurth C, Schmid JC, Weber LM, von Dincklage F, Lask A, Strauchmann J, Pratschke J, Rückert JC, Neudecker J, Dziodzio T.   +10 more
europepmc   +1 more source

Longitudinal genome‐wide aneuploidy measurements in circulating cell‐free DNA to predict lack of benefit from pembrolizumab in patients with metastatic urothelial cancer

Molecular Oncology, EarlyView.
Many patients with urothelial cancer do not benefit from treatment with pembrolizumab, while at risk of severe side effects. Changes in the levels of circulating tumor DNA early during treatment, measured by a simple and affordable assay that can be easily implemented in the clinic, can be used as a prognostic tool to identify these patients.
Youssra Salhi, Stavros Makrodimitris, Sandra van Wilpe, Iris te Paske, Vanja de Weerd, Corine M. Beaufort, Hans M. Westgeest, Jens Voortman, Maureen J. B. Aarts, Maud Rijnders, Astrid A. M. van der Veldt, Ronald de Wit, Niven Mehra, Saskia M. Wilting, Debbie G. J. Robbrecht   +14 more
wiley   +1 more source

Use of patient-reported outcome measures in everyday clinical practice in ophthalmology: results of a European multicountry survey. [PDF]

Br J Ophthalmol
Ernst SK, Jones PR, Somfai GM, Becker MD, Terheyden JH.   +4 more
europepmc   +1 more source

MITF maintains genome stability in nonmelanocyte lineages

Molecular Oncology, EarlyView.
MITF is essential for melanocyte survival and acts as an oncogene in 10%–20% of melanomas. We show that MITF depletion causes genome instability in nonmelanocytic cells, leading to LATS2‐mediated P53 activation, cell cycle arrest, and apoptosis. This study highlights the role of MITF as a genome maintenance factor beyond the melanocyte lineage. Created
Drifa H. Gudmundsdottir, Adrián López García de Lomana, Thejus B. Venkatesh, Kritika Kirty, Snaevar Sigurdsson, Linda Vidarsdottir, Ramile Dilshat, Erla Sveinbjornsdottir, Snaedis Ragnarsdottir, Daniel H Magnusson, Maria R. Bustos, Eirikur Steingrimsson, Thorkell Gudjonsson, Stefan Sigurdsson   +13 more
wiley   +1 more source

Patient-Reported Outcome Measures in Fetal Medicine: A Pilot Feasibility Study. [PDF]

Prenat Diagn
Crombag NMTH, Teeuwen B, Akkerman EMP, Adriaanse BME, Depla AL, Franx A, Oerlemans AJM, Stemkens D, Henneman L, Bekker MN.   +9 more
europepmc   +1 more source